Expertise in
6
conditions

Eric Francois

Nice, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
6
conditions
Nice, FR 

Overview

Eric Francois practices practicing medicine in Nice, France.

Mr. Francois is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Squamous Cell Carcinoma of the Anal Canal (SCAC), Colorectal Cancer, Anal Cancer, and Dihydropyrimidine Dehydrogenase Deficiency.

He is actively involved in clinical research, co-authoring 105 peer reviewed articles and participating in 15 clinical trials.

Gender

Male

Locations

Nice, France
Other Locations
Lyon, France
Paris, France
R&D Unicancer And Sorbonne Université, Dijon, France
Angers, France
Sophia Antipolis, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Multicentric Phase II-III Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma After a Favorable Response to Induction Chemotherapy
Multicentric Phase II-III Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma After a Favorable Response to Induction Chemotherapy
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Other, Radiation, Procedure, Drug
Study Phase: Phase 2/Phase 3
Phase II Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life
Phase II Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life
Enrollment Status: Completed
Publish Date: August 31, 2026
Intervention Type: Radiation, Drug
Study Drugs: 5-Fluorouracil, Mitomycin C
Study Phase: Phase 2
Impact of a Telephonic Monitoring During Neo Adjuvant or Adjuvant Chemotherapy
Impact of a Telephonic Monitoring During Neo Adjuvant or Adjuvant Chemotherapy
Enrollment Status: Completed
Publish Date: April 23, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma
A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 15, 2026
Intervention Type: Drug
Study Drugs: Gemcitabine, Paclitaxel
Study Phase: Phase 3
European Phase III Study Comparing a Radiation Dose Escalation Using 2 Different Approaches : External Beam Radiation Therapy Versus Endocavitary Radiation Therapy With Contact X-ray Brachytherapy 50 kiloVolts (kV) for Patients With Rectal Adenocarcinoma
European Phase III Study Comparing a Radiation Dose Escalation Using 2 Different Approaches : External Beam Radiation Therapy Versus Endocavitary Radiation Therapy With Contact X-ray Brachytherapy 50 kiloVolts (kV) for Patients With Rectal Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Device, Drug, Radiation
Study Phase: Phase 3
Phase III Study to Evaluate the Quality of Life in Elderly Patients With Metastatic Colorectal Cancer Receiving First-line Therapy Based on Simplified Geriatric Parameters.
Phase III Study to Evaluate the Quality of Life in Elderly Patients With Metastatic Colorectal Cancer Receiving First-line Therapy Based on Simplified Geriatric Parameters.
Enrollment Status: Active_not_recruiting
Publish Date: July 18, 2025
Intervention Type: Drug
Study Phase: Phase 3
Multicenter Randomized Phase II Study Comparing the Effectiveness and Tolerance of Avelumab Versus Standard 2nd Line Treatment Chemotherapy in Patients With Colorectal Metastatic Cancer With Microsatellite Instability (MSI)
Multicenter Randomized Phase II Study Comparing the Effectiveness and Tolerance of Avelumab Versus Standard 2nd Line Treatment Chemotherapy in Patients With Colorectal Metastatic Cancer With Microsatellite Instability (MSI)
Enrollment Status: Completed
Publish Date: June 29, 2025
Intervention Type: Drug
Study Drugs: FOLFOX Regimen, FOLFIRI Protocol, Avelumab, Panitumumab, Aflibercept
Study Phase: Phase 2
Randomized Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer
Randomized Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer
Enrollment Status: Completed
Publish Date: June 12, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Phase 3
Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: FOLFIRINOX, LV5FU2, FOLFIRI.3, Gemcitabine
Study Phase: Phase 2
A Phase III Study Evaluating Two Neoadjuvant Treatments Radiochemotherapy (5 Weeks - 50Gy+Capecitabine) and Radiotherapy (1week - 25Gy) in Patient Over 75 With Locally Advanced Rectal Carcinoma
A Phase III Study Evaluating Two Neoadjuvant Treatments Radiochemotherapy (5 Weeks - 50Gy+Capecitabine) and Radiotherapy (1week - 25Gy) in Patient Over 75 With Locally Advanced Rectal Carcinoma
Enrollment Status: Completed
Publish Date: October 13, 2023
Intervention Type: Radiation, Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

105 Total Publications

Prognostic Values of Pre- and Post-Therapeutic FDG-PET in Anal Canal Cancer: Analysis of a Prospective Study.
Prognostic Values of Pre- and Post-Therapeutic FDG-PET in Anal Canal Cancer: Analysis of a Prospective Study.
Journal: Clinical colorectal cancer
Published: March 01, 2024

Frequently Asked Questions about Eric Francois

Is Eric Francois a top-rated expert for Squamous Cell Carcinoma of the Anal Canal (SCAC)?

MediFind is an objective health platform that identifies experts based on real-world data. Eric Francois is classified as an Elite expert for Squamous Cell Carcinoma of the Anal Canal (SCAC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Eric Francois participate in research or clinical trials?

Yes. Eric Francois has published 105 articles and abstracts on conditions like Squamous Cell Carcinoma of the Anal Canal (SCAC). You can view a list of Eric Francois's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Francois's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile